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ABSTRACT Coronavirus disease 2019 (COVID-19) has wreaked havoc across the
globe; although the number of cases in Africa remains lower than in other regions,
it is on a gradual upward trajectory. To date, COVID-19 cases have been reported in
54 out of 55 African countries. However, due to limited severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) real-time reverse transcription-PCR (rRT-PCR) test-
ing capacity and scarcity of testing reagents, it is probable that the total number of
cases could far exceed published statistics. In this viewpoint, using Ghana, Malawi,
South Africa, and Zimbabwe as examples of countries that have implemented differ-
ent testing strategies, we argue that the implementation of sample pooling for rRT-
PCR over antibody rapid diagnostic testing could have a greater impact in assessing
disease burden. Sample pooling offers huge advantages compared to single test
rRT-PCR, as it reduces diagnostic costs, personnel time, burnout, and analytical run
times. Africa is already strained in terms of testing resources for COVID-19; hence,
cheaper alternative ways need to be implemented to conserve resources, maximize
mass testing, and reduce transmission in the wider population.
KEYWORDS antibody rapid diagnostic test, sample pooling, rRT-PCR, COVID-19,
Africa
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak was firstreported in Wuhan, China, in December 2019, and it has spread throughout the
world with an unprecedented impact on humanity (1). The disease later termed
coronavirus disease 2019 (COVID-19) has now been reported to have affected more
than 6.2 million people worldwide, culminating in more than 376,000 deaths by 2 June
2020 (2). In Africa, COVID-19 has been reported in 54 countries, with a cumulative
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155,610 confirmed cases and 4,429 deaths (3). With more than 3 billion people under
COVID-19-induced lockdown worldwide, accompanied by the attendant negative im-
pact on global economies, governments are racing to flatten the epidemic curve of
COVID-19 in both space and time (4, 5). Some of the policies imposed by governments
to flatten the curve include travel bans, lockdowns, quarantining, and widespread mass
testing using real-time reverse transcription PCR (rRT-PCR) (4, 5).
In order to achieve gains from these implemented measures and to reduce the
burden of COVID-19 cases on societies and economies, it is critical to implement
diagnostic strategies with high analytical sensitivity and specificity to enable early
detection of SARS-CoV-2 cases for isolation, contact tracing, care, and management.
International collaborative efforts initiated after the emergence of the SARS-CoV-2
pandemic led to the development of rRT-PCR diagnostic assays to ascertain cases
and track the outbreak (5, 6). The rRT-PCR is reported to have a diagnostic
sensitivity of 88 to 99% and a diagnostic specificity of 77 to 100% (7). This
development thus accelerated the definitive diagnosis of asymptomatic, presymp-
tomatic, and symptomatic cases (6).
Due to limited SARS-CoV-2 rRT-PCR testing capacity and scarcity of testing reagents
in many geographical regions, including Africa, it is clear that the total number of
COVID-19 cases is probably much higher than published confirmed statistics (8). Using
Ghana, Malawi, South Africa, and Zimbabwe as examples of countries that have
implemented different testing strategies, we argue that the implementation of sample
pooling for rRT-PCR over antibody rapid diagnostic testing (RDT) could have a greater
impact on the early detection of active COVID-19 cases and assist in curbing the spread
of the disease, whereas antibody-based RDTs may help to ascertain community sero-
prevalence and estimate potential herd immunity benefits.
Case studies of COVID-19 diagnostic strategies in Africa. (i) A case study of
Ghana. Ghana is one of the few countries that implemented sample pooling strategy
for COVID-19 rRT-PCR testing and confirmation (9, 10). However, at the onset of the
pandemic, the country implemented single sample rRT-PCR testing before scaling it
upwards through sample pooling (10, 11). As of 31 May 2020, a total of 219,825 tests
had been conducted by the seven government-affiliated laboratories spread across
Ghana (12). Through sample pooling, approximately 0.71% of the total population
have been tested, giving rise to 8,297 confirmed COVID-19 cases (positivity rate of
3.77%) (12). Ghana is the second highest ranked African country in terms of testing
capacity. The COVID-19 testing strategy implemented pooled at most 10 different
patient samples for amplification prior to testing. This strategy has tremendously
improved Ghana’s COVID-19 testing capacity and definitive diagnosis.
(ii) A case study of Malawi. As of 1 June 2020, Malawi had conducted 5,505 rRT-PCR
tests, yielding 358 COVID-19 cases (13). Malawi has the highest SARS-CoV-2 positivity
rate (6.50%) in the region, despite its low testing rate of only0.03% of the population
tested so far (13). The country recently increased its COVID-19 testing sites to 14 in
order to expand geographic coverage. Owing to the low testing capacity, Malawi needs
to be more restrictive in choosing who to test in order to maximize benefits from its
limited resources.
(iii) A case study of South Africa. South Africa has conducted 742,742 rRT-PCR
tests, yielding 35,812 COVID-19 cases and a positivity rate of 4.82% (14). It is the leading
African country in terms of testing capacity, with 1.25% of its population having been
tested for COVID-19 by 1 June 2020. South Africa is currently conducting individual
sample testing using several in-house and commercial PCR assays to test for the
presence of SARS-CoV-2 RNA (15). However, most diagnostic laboratories are over-
whelmed, as the country is conducting targeted community symptom screening and
testing for both symptomatic and asymptomatic individuals in some provinces (15, 16).
Novel screening and testing strategies need to be adopted in order to manage and
improve the capacity and sample turnaround testing time in diagnostic laboratories.
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(iv) A case study of Zimbabwe. Recently, the Ministry of Health and Child Care
(MoHCC) of Zimbabwe introduced antibody RDT as a screening test strategy for
SARS-CoV-2 to complement the rRT-PCR assays being offered in government reference
laboratories, state universities, and private laboratories. Despite this development, the
country still has limited capacity to conduct mass testing (17). As of 1 June 2020, a total
of 46,021 COVID-19 tests (28,112 RDTs and 18,709 RT-PCR) had been conducted, with
203 confirmed cases (18). The current testing coverage translates to approximately
0.13% of the population tested by rRT-PCR/Xpert Xpress for SARS-CoV-2 with a 1.09%
positivity rate. Furthermore, many of the RDTs in current use have not been validated
or verified for use within this population. Thus, the current rRT-PCR undertesting raises
the concern that many infected individuals are probably going undiagnosed.
Implementation of different testing strategies for COVID-19. (i) Sample pool-
ing for rRT-PCR. Sample pooling was first suggested by Robert Dorfman in 1943 as a
way of optimizing syphilis testing, and since then, it has been applied in surveillance
and screening for infections such as human immunodeficiency virus (HIV), hepatitis B
virus (HBV), hepatitis C virus (HCV), malaria, and influenza virus (19–25). Sample pooling
has popularly been employed in serological work but also in molecular diagnostics and
research. It helps to lower experimental costs and personnel time and reduces analyt-
ical run times while maximizing the level of surveillance and accuracy of the diagnostic
test (19, 21, 24, 26). In public health emergencies, such as the COVID-19 pandemic,
rapidly growing workloads can outstrip laboratory testing capacity, resulting in reagent
shortages and personnel burnout (16, 27). Thus, in large populations with a low disease
prevalence (10%), sample pooling provides a cost-effective strategy for screening
asymptomatic and presymptomatic individuals (25, 27–29). Two different sample pool-
ing strategies can be used, namely, single-step pools, where prevalence and confidence
intervals are calculated based on pool results (30), or multiple-step pools, where
individual samples from a positive pool are retested to identify the number of positive
individuals per pool (31, 32). The latter is more useful for COVID-19, as the individuals
need to be identified for isolation, contact tracing, care, and treatment.
The use of a single test to screen groups of more than two people, though labor
intensive, provides a comprehensive, rapid, and localized mass testing strategy re-
quired to identify cases acutely and minimize spread of disease. However, the antici-
pated cost reduction becomes meaningful only if statistical equivalence between the
pooled and nonpooled experimental setups is achieved and maintained (33). In vitro
and in silico studies of pooling nasopharyngeal samples for rRT-PCR assays, have
reported the optimal pool size (p), to be five samples per pool (28, 29). On account of
variances in different PCR assay limits of detection (LoD), it is paramount to validate the
use of pooled samples and rule out false-negative findings as a result of sample
dilution. Of note, p can be scaled up to p  32 (29, 34–36), where the concentration of
RNA by elution/lyophilization becomes necessary to curb the risk of false-negative
results due to sample dilution (37). Fundamental principles for successful application of
sample pooling are subject to the assay’s sensitivity, specificity, and limit of detection
and the prevalence of disease in the population.
COVID-19 is estimated to have a high effective reproductive number R0 (ranging
from 1.4 to 6.49, with a median value of 2.79) (38). Employing sample pooling for
contact tracing ensures swift case identification, with less resources used to arrest
community transmissions (38–40). Meanwhile, for frontline health care workers (HCW)
interfacing with COVID-19 patients, sample pooling can be modeled to cluster high-risk
individuals in order to concentrate the positivity rate to a few pools, thereby further
conserving resources.
Sample pooling is also associated with limitations such as reduced test sensitivity in
settings with very low infection prevalence (21, 41). Thus, a diagnostic laboratory has
to optimize the pool size based on the prevalence of the infection within the society.
Additionally, it is also critical for laboratories to understand that a negative pool result
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would not distinguish between a true negative and an indeterminate or inconclusive
result due to poor specimen collection or handling (24).
(ii) Antibody RDT testing for COVID-19. Any acceptable screening or first-line test
should ideally have a high clinical diagnostic sensitivity, whereas the consecutive
confirmatory test needs to have a high specificity (5, 7, 8, 42, 43). Despite this, some
low-medium income countries (LMICs) in Africa have implemented unverified RDTs for
COVID-19 into their testing and surveillance protocols. Whether these RDTs are yielding
intended results remains to be verified. However, cheaper but well-validated serological
assays are essential to complement the fairly expensive rRT-PCR diagnostic assays, to
accurately assess the COVID-19 disease burden within communities and map global
exposure (6). Samples can also be pooled as is applied when screening blood products
for infections such as HBV and HCV to achieve maximum testing benefit (44).
Testing of specific antibodies against SARSCoV2 in patient blood is a good choice
for rapid and simple diagnosis of COVID19 (45). However, early studies have reported
that the majority of COVID-19 patients seroconvert between days 7 and 11 after
exposure to SARS-CoV-2, thus rendering antibody testing questionable in the setting of
an acute illness (43, 46, 47). Moreover, RDT kits for SARS-CoV-2 antibodies have an
analytical sensitivity of 69 to 88% for IgM and 90 to 99% for IgG (7, 8, 42, 45). Therefore,
RDTs pose the following questions: When to test? Whom to test? What to test? How
often to test? What to do with test results? (43). Although validated RDTs can be used
in seroprevalence studies, data generated from the use of RDTs may not be reliable
unless conducted systematically and periodically due to the wide variation in duration
of time to seroconversion among individuals (16).
Scenarios where rRT-PCR sample pooling or antibody RDT may be employed.
(i) Establishing the status of an asymptomatic individual. COVID-19 follows an
asymptomatic disease course before symptoms appear, thus causing increased spread
of the disease (48, 49). Since antibodies can be detected only 6 to 29 days after
symptom onset, antibody RDTs may result in false-negative COVID-19 status, which will
in turn delay management and contact tracing, thus allowing propagation of infections
within communities. On the other hand, various studies using rRT-PCR have demon-
strated asymptomatic carriage in obstetric patients (13.7%), Diamond Princess ship
passengers (17.9%), and skilled nursing facility residents (35.6%) (48–50). It should,
however, be stressed that in the highlighted studies, the asymptomatic carriers con-
tributed 50% of the COVID-19 cases.
(ii) Testing health care workers and other employees providing essential
services. Health care workers and essential service employees showing no symptoms
but continuously interacting with the general population have been shown to be
capable of transmitting SARS-CoV-2, as demonstrated in the skilled nursing facility
residents in New York (48). Mass testing for asymptomatic HCWs and essential service
employees is therefore critical in order to mitigate workforce depletion by unnecessary
quarantine, reduce spread of atypical, mild, or asymptomatic cases, and protect the
health care and essential service workforce (51). Thus, it is crucial to set a reasonable
testing schedule and frequency using pooled sampling rRT-PCR after assessing their risk
profile to allow early detection and intervention in asymptomatic and presymptomatic
individuals. This can be done by splitting employees working in the same department
into groups and staggering testing of these groups to help identify any potential
circulation (thus need of contact tracing) of the disease among staff while minimizing
once off use of resources.
Asymptomatic and presymptomatic HCWs and essential service workers are an
underappreciated potential source of infection and worthy of testing to reduce
in-hospital transmission and community spread (51, 52). Workers returning to work
may be tested by validated RDTs as a means of tracing possible missed asymptom-
atic/presymptomatic and symptomatic cases. Furthermore, routine temperature
checks must be conducted daily; collectively, this will aid in reducing community
spread.
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(iii) Contact tracing. Elucidation of the chain of infection and identification of the
source of COVID-19 infections are crucial for effective disease containment (52, 53).
Although the rRT-PCR option offers a diagnostic solution and is important for estab-
lishing infection status in contacts of an index case, this approach might not be
diagnostically useful in patients who have recovered and are no longer shedding the
virus (53). The duration of viral shedding for COVID-19 remains uncertain (54), but data
from SARS-CoV indicate that 21 days after symptom onset, 53% of cases achieved viral
clearance in nasopharyngeal aspirate samples (55). Thus, serological tests are more
useful in identifying convalescent cases, ascertaining seroprevalence, and an accurate
denominator for the case fatality rate (53).
(iv) Establishing status in symptomatic patients. It is critical to establish the
status of any person exhibiting COVID-19-related symptoms as soon as possible to
enable appropriate management. As previously emphasized, RDTs have a limitation as
far as detection at early onset is concerned and thus may not be very useful.
(v) Establishing past exposure and immunity to COVID-19. It is critical to identify
individuals with past exposure or those that have recovered from SARS-CoV-2 by
testing for IgM/IgG antibodies. However, whether the immune response following
exposure to SARS-CoV-2 is long-lasting and protective against reinfection remains an
issue of debate (5, 47, 56). Furthermore, diagnostic tests that detect antibodies to
SARS-CoV-2, including rapid immunodiagnostic tests, need extensive validation to
determine their clinical utility (57).
Conclusions. The use of sample pooling for rRT-PCR testing particularly in Africa, to
screen for active COVID-19 cases has a great advantage over single test rRT-PCR, as it
helps lower diagnostic costs, personnel time, and burnout and also reduces analytical
run times (27, 29, 37, 48, 58). Africa is already strained in terms of testing resources for
COVID-19; hence, cheaper alternatives need to be implemented to conserve resources,
maximize mass testing, and reduce transmission in the wider population. Currently,
WHO does not recommend the use of antibody- and antigen-detecting rapid diagnos-
tic tests for patient care but encourages their extensive validation to establish their
usefulness in disease surveillance and epidemiologic research (57, 59). Health care
workers and other essential service workers, particularly those working in cities and
towns with confirmed cases, are a key reservoir for the transmission of COVID-19 due
to their interface with patients and the wider population, respectively. Thus, it is crucial
to set a reasonable testing schedule and frequency using pooling of samples for
rRT-PCR after assessing their risk profile to allow early detection and intervention in
asymptomatic and presymptomatic individuals. Blanket testing of asymptomatic front-
line staff is a futile exercise that will not add value to this fight.
Key terms and definitions. Asymptomatic, laboratory-confirmed COVID-19 case
who does not display symptoms; presymptomatic, an individual who has been exposed
to the virus (becoming infected) but has not developed symptoms yet; seroconversion,
the transition from a seronegative condition—where no antibodies are detectable in
the serum or are present at titers below the limit of detection— to a seropositive
condition, in which antibodies are detectable in serum samples; symptomatic, an
individual who has developed signs and symptoms compatible with COVID-19; sensi-
tivity, the ability of a diagnostic test to correctly identify all patients with the disease;
specificity, the ability of a diagnostic test to correctly identify all patients who do not
have a disease.
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